Azafaros
Azafaros is a clinical-stage biotech company developing nizubaglustat, an orally available, brain-penetrant small molecule with a unique dual mode of action, targeting key pathways in GM1/GM2 gangliosidoses, Niemann-Pick type C (NPC), and other severe metabolic disorders. Following a successful Ph 2 study, Azafaros is preparing for global Ph 3 trials in GM1/GM2 gangliosidoses and NPC. In parallel, the company continues to expand its pipeline through cutting-edge research.
Date, time and room information
May 6, 14:45 - 15:00, room Montreal
Category
Clinical stage development company
Title of the presentation
Nizubaglustat: a solution for neurological manifestations of multiple lysosomal storage disorders
Speaker information
| Name | Position | Institution |
|---|---|---|
| Stefano Portolano | CEO | Azafaros |
Host and event manager:
Logistics and marketing partner:
